What are the latest advances in Congenital bilateral perisylvian syndrome?

Congenital bilateral perisylvian syndrome (CBPS) is a rare neurological disorder characterized by pseudobulbar palsy, epilepsy, and developmental delays, currently managed primarily through supportive multidisciplinary therapies. While there is no curative gene therapy or pharmaceutical treatment, recent research is shifting toward advanced neuroimaging and genetic sequencing to better understand the underlying cortical malformations associated with this condition.

What are the current research directions for Congenital bilateral perisylvian syndrome?

Research into Congenital bilateral perisylvian syndrome is currently focused on identifying the genetic drivers of polymicrogyria, the hallmark cortical malformation seen in this condition. Because the syndrome can be caused by diverse genetic mutations or prenatal environmental insults, researchers are utilizing whole-exome and whole-genome sequencing to map specific pathogenic variants. Understanding these mechanisms is the first step toward developing future precision medicine approaches, though clinical application remains in the early stages of investigation.

Are there new diagnostic tools or biomarkers for this condition?

The diagnostic landscape for Congenital bilateral perisylvian syndrome has improved significantly with the widespread availability of high-resolution 3T MRI technology. Clinicians are increasingly using advanced neuroimaging to identify the characteristic bilateral perisylvian polymicrogyria earlier in life. Furthermore, international research consortia are working to create standardized phenotypic databases, which help distinguish Congenital bilateral perisylvian syndrome from other forms of malformations of cortical development (MCD). These efforts allow researchers to correlate specific genetic findings with clinical outcomes more accurately.

What is the current status of clinical trials and therapeutic breakthroughs?

Currently, there are no approved disease-modifying therapies for Congenital bilateral perisylvian syndrome, and there are no active, large-scale clinical trials specifically targeting the underlying cause of the syndrome. Management is strictly symptomatic, focusing on the following areas:

• Seizure management: Utilizing anti-seizure medications (ASMs) to address epilepsy, which affects approximately 75% of individuals with Congenital bilateral perisylvian syndrome.


• Speech and Language Therapy: Targeted interventions for oromotor dysfunction and dysarthria.


• Nutritional Support: Gastrostomy tube placement is often utilized for patients experiencing significant dysphagia to prevent aspiration.


• Physical and Occupational Therapy: To address the spasticity and motor delays associated with the condition.

How can patients get involved in research?

Given the rarity of Congenital bilateral perisylvian syndrome, patient participation in natural history studies is vital. These studies track how the condition progresses over time, providing the data necessary to design future clinical trials. Patients and families can find ongoing research through the following resources:

• ClinicalTrials.gov: Search for "polymicrogyria" or "bilateral perisylvian syndrome" to identify observational studies that may be recruiting.


• Patient Registries: Joining platforms like DiseaseMaps.org, where 45 members currently share their experiences, helps researchers identify participant cohorts for future studies.


• Specialized Centers: Consult with neurology departments at major academic medical centers that specialize in pediatric epilepsy and cortical malformations.

Next steps

• Schedule a consultation with a pediatric neurologist or a geneticist to ensure your child has the most up-to-date genetic testing.


• Connect with the Congenital bilateral perisylvian syndrome community on DiseaseMaps.org to share insights and learn from others' care experiences.


• Request a referral to a multidisciplinary feeding and speech clinic to optimize oromotor function.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Congenital bilateral perisylvian syndrome profile.


• Orphanet: Rare disease database entry for Bilateral perisylvian polymicrogyria.


• OMIM (Online Mendelian Inheritance in Man): Clinical synopsis for Perisylvian polymicrogyria.


• PubMed: Recent literature reviews on the genetic architecture of cortical malformations.